Oral ONC201 in Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 19, 2017

Primary Completion Date

September 17, 2019

Study Completion Date

December 16, 2019

Conditions
Multiple Myeloma
Interventions
DRUG

ONC201

375 mg or 625 mg ONC201

DRUG

Dexamethasone

20 mg dexamethasone

Trial Locations (2)

19111

Fox Chase Cancer Center, Philadelphia

10029-6574

The Mount Sinai Medical Center, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Oncoceutics, Inc.

INDUSTRY

lead

Jazz Pharmaceuticals

INDUSTRY